Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hikma Pharmaceuticals PLC - London-based pharmaceutical company - Appoints Laura Balan and Victoria Hull as independent non-executive directors with effect from October 1 and November 1, respectively. Balan worked for 17 years at the Capital Group Co, where she covered European healthcare and pharmaceutical sectors. Hull is currently a non-executive director for IQE PLC, Alphaware IP Group PLC and Network International Holdings PLC. Previously she was chief legal officer & executive director at Invensys PLC, now Schneider Electric, from 2001 to 2014.
Says these two new appointments bring the level of female representation on the board to 40%, after shareholders voted against the re-election of Pat Butler at April's annual general meeting. After the AGM, female representation fell to 22% from 30%. Says the board has diversity targets following Hampton-Alexander Review and Parker Review.
Executive Chair & Chief Executive Said Darwazah comments: ‘Laura brings extensive knowledge of the global healthcare industry and an excellent track record of investing in a broad range of healthcare businesses. She is a strong strategic thinker who will add value to the board. Victoria brings broad experience across a range of businesses, having held executive and non-executive director roles. She has strong experience of the UK listed environment and brings extensive Merger & Aquisition experience to the board’.
Current stock price: 1,368.00 pence
12-month change: down 44%
Copyright 2022 Alliance News Limited. All Rights Reserved.